A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.